PT-141 vs Melanotan II
An approved melanocortin agonist versus an unapproved one.
Bremelanotide (melanocortin receptor agonist)
An FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women.
Melanotan II (melanocortin receptor agonist)
An unapproved melanocortin agonist studied for skin pigmentation and libido, with notable safety concerns.
| Attribute | PT-141 | Melanotan II |
|---|---|---|
| Category | Melanocortin | Melanocortin |
| FDA status | FDA-approved (Vyleesi) | Not approved; flagged by regulators |
| Half-life | ~2.7 hours | ~1 hour |
| Molecular weight | 1,025.2 Da | 1,024.2 Da |
| Mechanism | Agonizes central melanocortin receptors (notably MC4R) involved in sexual arousal and desire pathways. | Broadly agonizes melanocortin receptors, stimulating melanogenesis (MC1R) and central pathways affecting appetite and sexual function (MC4R). |
| Legal status (US) | FDA-approved, prescription only | Not approved; sale flagged by FDA |
Frequently asked questions
What is the difference between PT-141 and Melanotan II?
PT-141: An FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women. Melanotan II: An unapproved melanocortin agonist studied for skin pigmentation and libido, with notable safety concerns.
Which has stronger research evidence, PT-141 or Melanotan II?
PT-141 is rated Strong and Melanotan II is rated Preliminary for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are PT-141 and Melanotan II FDA-approved?
PT-141: FDA-approved (Vyleesi). Melanotan II: Not approved; flagged by regulators.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.